Drug Patents owned by Glaxo Grp England

1. Drug name - INCRUSE ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7498440 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US7488827 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Dec, 2027

(5 years from now)

CN1976701A GLAXO GRP ENGLAND Machrs Antagonist
May, 2012

(10 years ago)

IN255064B GLAXO GRP ENGLAND 4-[Hydroxy(Diphenyl)Methyl]-1-(2-[(Phenylmethyl)Oxy]Ethyl}-1-Azoniabicyclo[2.2.2.]Octane Bromide
Apr, 2025

(2 years from now)

IN200605413P1 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2570128A1 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2570128B1 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A4 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177B1 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A2 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists Apr, 2025

(2 years from now)

US8183257 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists Jul, 2025

(2 years from now)

US9333310 GLAXO GRP ENGLAND Medicament dispenser Oct, 2027

(4 years from now)

US8113199 GLAXO GRP ENGLAND Counter for use with a medicament dispenser Oct, 2027

(5 years from now)

US8161968 GLAXO GRP ENGLAND Medicament dispenser Feb, 2028

(5 years from now)

US8201556 GLAXO GRP ENGLAND Medicament dispenser Feb, 2029

(6 years from now)

US8534281 GLAXO GRP ENGLAND Manifold for use in medicament dispenser Mar, 2030

(7 years from now)

US8746242 GLAXO GRP ENGLAND Medicament dispenser Oct, 2030

(8 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 62.5MCG BASE/INH POWDER;INHALATION Prescription

availability in other generic markets.

Click on the highlighted region to filter.